Skip to content
MarketScale
‹ Back to IndustriesSciences

How the Indestructible Molecule that is PFAS Effects the Environment

In the most recent episode of “There’s More to IT,” host Jason Claybrook discussed the widespread exposure of Per and Polyfluoroalkyl Substances, better known as PFAS, in various aspects of everyday life. His guest was Yuran Li, the director of MS Commercial Strategies at Alternative Biomedical Solutions — a Texas based laboratory. The two talked…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Jason Claybrook · EnvironmentEnvironmental Protection AgencyHealthMolecule
Share

Key takeaways

01

In the most recent episode of “There’s More to IT,” host Jason Claybrook discussed the widespread exposure of Per and Polyfluoroalkyl Substances, better known as PFAS, in various aspects of everyday life.

02

His guest was Yuran Li, the director of MS Commercial Strategies at Alternative Biomedical Solutions — a Texas based laboratory.

In the most recent episode of “There’s More to IT,” host Jason Claybrook discussed the widespread exposure of Per and Polyfluoroalkyl Substances, better known as PFAS, in various aspects of everyday life. His guest was Yuran Li, the director of MS Commercial Strategies at Alternative Biomedical Solutions — a Texas based laboratory. The two talked about just what PFAS is, and why the molecules’ existence is harmful.

PFAS is a manmade chemical that repels water and oil, which also makes it a highly preferable component for some commonly-used products. This can include cookware, food wrappings, and paint, according to Li. The first use of PFAS began in the 1940s, and it evidently found its way into various products due to its resistant qualities. And due to that fact, the initial inference of the safety of PFAS was misleading, per Li.

“There is no natural occurrence of this type of molecule, and because everything gets repelled from it, there was always this assumption early on when it was invented, that it’s harmless,” said Li.

But decades later and after many studies, even by the U.S. Environmental Protection Agency (EPA), it has been concluded the concerns regarding PFAS are major harm to the environment and living beings.

PFAS does not break down into the environment the way other molecules can, which means it presents a different type of danger for the environment. And just based on bioaccumulation, PFAS’ has found its way into every living organism, said Li.

Current studies are still in the early stages of determining just how toxic PFAS can be to the human body, and what levels would be considered a cause for immediate concern. But there is a connection between it and other health issues, said Li.

“Some of the early links were cancers, thyroid issues is one of the biggest ones being investigated at the moment, and pregnancy issues,” said Li.

People with major thyroid problems and hormonal imbalances were shown to have a lot of exposure to PFAS, added Li. But he stated that the studies between PFAS and infertility is a growing concern that is taking precedence.

Even more daunting is the formidablilty of PFAS. Being that it cannot break down environmentally, that also means it doesn’t break down in the body either. Subsequently, the response for health issues or symptoms related to PFAS is basic treatment. But even treatment like chemotherapy or cancer medications can’t break down the substance.

Li joked that even diamonds aren’t as long-lasting, and stated that PFAS is expected to be around for a long time due to the weight of effort that even needs to be made just to fully eliminate it. For example, if PFAS ends up in wildlife, it is expected to be there practically forever.

“It will take millions of years before they would even begin to start breaking down — that’s how strong that molecules’ bonds are,” said Li. “Right now the only method really of getting rid of PFAS is really high heat incineration.”

Only extremely high heat can destroy PFAS, but even if that method was widely utilized, it would create another domino effect of environmental issues such as harming the natural water supply.

The Industry That is Depending on Science and Regulation to Grow

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

About the author

JC
Jason Claybrook

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

JC
Jason Claybrook

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512